Answers are grounded in this paper and cite their sources.
Background Adjuvant chemotherapy improves survival after resection of pancreatic ductal adenocarcinoma (PDAC), but the comparative outcomes of gemcitabine monotherapy (G) and gemcitabine plus S-1 (GS) in routine practice remain uncertain. This study aimed to analyze the associations of chemotherapy regimen and treatment completion with survival. Methods We retrospectively evaluated patients undergoing curative-intent resection for PDAC at Peking University First Hospital between January 2010 and April 2022. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards models. Sensitivity analyses included modeling chemotherapy initiation as a time-dependent exposure and comparing restricted mean survival time (RMST) between the G and GS groups over a 36-month horizon. Results The cohort included 245 patients, of whom 173 received postoperative chemotherapy; 46 received G and 90 received GS. Date-derived survival analyses included 242 evaluable patients. Median OS was 30.00 months (95% CI, 19.88–36.07) and median DFS was 15.93 months (95% CI, 12.52–24.57). For GS versus G, adjusted HRs were 1.28 (95% CI, 0.72–2.28) for OS and 1.36 (95% CI, 0.78–2.37) for DFS. Conclusions No significant differences in OS or DFS were observed between G and GS in this cohort. The exploratory associations between chemotherapy completion and survival need confirmation in studies that account for treatment timing and potential confounding.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: